Amex Biotechnology Index (BTK)

QUOTE AND NEWS
Clusterstock  Mar 27  Comment 
Credit Suisse analysts say biotechs are not in a bubble. Still, in a note Friday, the firm presents  evidence for the industry being in in a bubble, and other evidence that it definitely isn't. The signs that there’s a bubble, they...
GenEng News  Mar 19  Comment 
Eli Lilly will join in developing and commercializing Hanmi Pharmaceutical's Phase I compound HM71224 for autoimmune and other diseases, in a deal that could generate up to $690 million, plus royalties, for Hanmi. HM71224 is an oral Bruton's...
MedPage Today  Dec 11  Comment 
(MedPage Today) -- Responses, stable disease increase across range of doses.
Benzinga  Oct 23  Comment 
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting...
Forbes  Mar 13  Comment 
Immunokinase-directed therapeutics have been one of the highest returning drug classes for biotech investors in recent years.  Drugs that inhibit the JAK family, BTK, Syk, and PI3Kd have all generated impressive clinical validation in B- and...
Benzinga  Dec 11  Comment 
Pharmacyclics (Nasdaq: PCYC) and its collaborators provided clinical and pre-clinical presentations on ibrutinib and ibrutinib combinations at the 2012 ASH Annual Meeting. Ibrutinib inhibits Bruton's tyrosine kinase (BTK), which is known to be...
Forbes  Dec 8  Comment 
Biotechnology stocks haven’t produced much excitement for investors this year , partly because the Presidential elections and national politics usurped much of the news headlines. So Wall Street and most investors have had little chance or...
StreetInsider.com  Jun 18  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Pharmacyclics+%28PCYC%29+Updates+Safety.Efficacy+on+Two+BTK+Inhibitor+Ibrutinib+Trials/7522155.html for the full story.
Benzinga  Jun 4  Comment 
Pharmacyclics, Inc (Nasdaq: PCYC) announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic...
Benzinga  Apr 30  Comment 
Tolero Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel therapeutics to treat cancer and other serious human diseases, and MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and...




RELATED WIKI ARTICLES
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki